New hope for sarcoma patients: drug combo aims to shrink tumors
NCT ID NCT06498648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new two-drug treatment for people with advanced soft tissue sarcomas (cancers of the muscles, fat, or other connective tissues). The drugs, abemaciclib and gemcitabine, work together to stop cancer cells from growing. The trial will compare this new combo to the usual treatment (gemcitabine plus docetaxel) to see if it works better and has fewer side effects. About 74 adults with certain types of sarcoma that have spread or cannot be removed by surgery can join.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED DEDIFFERENTIATED LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own immune cells fight advanced sarcoma?
- Can an immune-boosting drug make chemotherapy more effective against sarcoma?
- Immunotherapy boosts chemo against rare sarcomas?
- Could 5 days of radiation replace 25 for sarcoma patients?
- New mRNA shot targets Hard-to-Treat cancers in early human test
- New hope for sarcoma patients: drug slows tumor growth in late-stage trial